Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
And here is a sample of 3 policies we describe and how they alter the Reward Box shape and thus the risk and reward of developing particular types of drugs:pic.twitter.com/lJd213pOVo
Prikaži ovu nit -
these are really narrow areas of focus, but yes this point is often overlooked. But here is a graph that puts this in perspective for Neupogen, often touted as a 'success' story of biosimilar entry.pic.twitter.com/YabO9QsLAG
-
Policy goal: post exclusivity prices to marginal cost. Crude overlay of longer trend on
@ScottGottliebMD chart (ht@steveusdin1). Reminder launch is still multiples of marginal cost. Enormous oppty cost compared to price regulation AND no patient benefit. https://buff.ly/2YvBZVp https://twitter.com/ScottGottliebMD/status/1202723265539661825 …pic.twitter.com/6JYmsURCVz
-
Where is the gif for goal post moving? Oh I found it. The goal is marginal economic cost for all biologics post exclusivity. Not happening in these days.pic.twitter.com/yQcutf3bpY
-
trends in Diabetes incidence (percentages and counts) from CDC, 1958-2015. Seems a pity to abandon trying to treat this condition, ranked as #7 killer in the US (83,000 per year). https://www.cdc.gov/nchs/fastats/diabetes.htm …pic.twitter.com/2901GDqdNy
-
I am sure
@DusetzinaS will tweet about this too, and use both more and better gif's. And it will be:pic.twitter.com/ppsD6vpbHIPrikaži ovu nit -
Focusing on 2019 top 10 drugs in each category, savings if we had negotiated down to UK prices would have been just shy of $27B for one year across all payers. H.R.3 would save more. Abt $350B in Medicare alone over a decade, the Grassley-Wyden bill about $130B over a decade.pic.twitter.com/fzJVfNagVp
Prikaži ovu nit -
Top/bottom ranked states life expectancy has w/in state diff from top to bottom quartiles of 8-10 yrs. In other words, an unimaginable number of lost years of life and not plausible we can drug our way to ameliorating this problem, particularly with our focus on rare conditions. https://twitter.com/peterbachmd/status/1199363746201833472 …pic.twitter.com/NdKOXElsH0
-
One of the charts I showed with the uptick in 'deaths of despair' (not my term, I think Case and Deaton coined it). I don't think the best first answer to this is that we need new therapies for these problems, figuring out why we lost ground and getting it back probably is). https://twitter.com/peterbachmd/status/1199363746201833472 …pic.twitter.com/Kt19jZcSyn
-
Juul age verification system nicely summarized. Does this even count as making an effort? https://www.nytimes.com/2019/11/23/health/juul-vaping-crisis.html …pic.twitter.com/rZxuFji7Da
-
This is the problem with using percentages
#statsummit. NIH funding to DFCI over past 10 years appears in nominal dollars to be increasing. So I think 'filling the gap' is not a good summary, but it is a much more favorable narrative. https://report.nih.gov/award/index.cfm?ot=&fy=2009&state=&ic=&fm=&orgid=1464901&distr=&rfa=&om=y&pid=&view=state …pic.twitter.com/RbHI2otqKX
-
Looking forward to speaking at
#STATSummit, will cover innovation incentives and that they work, maybe too well. The gains are not distributed across society even though the costs are.pic.twitter.com/fS1CbW4AVM
-
Swag from
@HLTHEVENT#HLTH2019: Someone in marketing seems to have misunderstood the term "combination therapy." (actually#saferx anti-abuse packaging - H/T)pic.twitter.com/5JnPxzKyA7
-
Very flattered to have the chance to speak at
@fredhutch about the challenges currently posed by high drug prices (with some solutions thrown in).#hicorpic.twitter.com/vX2pAC5xi9
-
Looking forward to discussing drug pricing following the surprise appearance by Wendell Primus of
@SpeakerPelosi office. https://twitter.com/_jacquie_lee/status/1176233543166582786 …pic.twitter.com/53Ni3yUQxn
-
Must-read report from
@WaysandMeansGOP@WaysMeansDems on the yawning gap in drug prices between US and other countries, step-by-step empirically debunks the@phrma explanations, calls for negotiation. https://waysandmeans.house.gov/sites/democrats.waysandmeans.house.gov/files/documents/U.S.%20vs.%20International%20Prescription%20Drug%20Prices_0.pdf … Some killer graphs like this one on MS drugs#goboldlypic.twitter.com/zKPNDHRu6D
-
Wait, what? They call this result “positive”. HR of 0.99 and p = .95? https://twitter.com/adamfeuerstein/status/1171373852972265475 …pic.twitter.com/NLlsD5vXGL
-
GIF laden thread through the tall grass of various Part D restructuring proposals. https://twitter.com/DusetzinaS/status/1169354796530167809 …pic.twitter.com/yQ358NfYOa
-
Remember
$NVS referring to its subsidiary Avexis in the recent FDA data “issue” with Zolgensma? Time tested tactics perfected by$JNJ. They did it again today in the opiate settlement with OK. Cc @matthewherperpic.twitter.com/KcY1kUiXsz
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.